Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Preveceutical Medical Inc. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners but are concentrated within only 2 distinct art units. This suggests that while different individuals are reviewing the applications, they are working within a relatively narrow set of organizational groups at the USPTO.
The busiest examiner is KOMATSU, LI N, who is responsible for 1 pending office action. Because each of the 3 distinct examiners handles only 1 of the 3 pending office actions, the workload is evenly spread across the personnel. However, the fact that these 3 distinct examiners are housed in only 2 distinct art units means the practitioner may encounter similar examination cultures or internal guidelines across the different filings.
Navigating 3 pending office actions in the Biotechnology & Pharmaceuticals field requires the practitioner to be mindful of the overlap between the 2 distinct art units. While each of the 3 distinct examiners will have their own style, the shared art unit environments may lead to common themes in the rejections or requirements. The practitioner should coordinate responses to ensure that the strategy for the 1 pending office action under KOMATSU, LI N is consistent with the other pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOMATSU, LI N | 1 | 59.8% | +71.0% |
| BARSKY, JARED | 1 | 50.3% | +22.8% |
| BOWLES, DAVID PAUL | 1 | 69.6% | +28.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18711546 | PEPTIDES AND USES THEREOF | KOMATSU, LI N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18043398 | CANNABINOID FORMULATIONS AND METHODS OF USE | BARSKY, JARED | 66d overdue |
| 18711546 | PEPTIDES AND USES THEREOF | KOMATSU, LI N | — |
| 17424649 | A CYCLIC PEPTIDE | BOWLES, DAVID PAUL | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1628 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18711546 | PEPTIDES AND USES THEREOF | KOMATSU, LI N | 1658 | §103§112 | Non-Final OA | — | Pending | May 17, 2024 |
| 18043398 | CANNABINOID FORMULATIONS AND METHODS OF USE | BARSKY, JARED | 1628 | §103 | Final Rejection | 66d overdue | Pending | Feb 28, 2023 |
| 17424649 | A CYCLIC PEPTIDE | BOWLES, DAVID PAUL | 1654 | §112 | Final Rejection | — | Pending | Jul 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPreveceutical Medical Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Li N Komatsu has the most, with 1 of Preveceutical Medical Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
